- Clone:
- REA403 | TUGm2
- Type of antibody:
- Primary antibodies, Recombinant antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- FC Glossary
- Select a conjugate:
- Select a size:
Related products for CD132 Antibody, anti-mouse, REAfinity™
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Cells were incubated with an excess of purified unconjugated CD132 (REA403) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
Flow cytometric comparison of different clones for CD132. Splenocytes from C57BL/6 mice were stained with CD132 antibodies followed by a suitable counterstain. As a control, CD132 antibody staining was omitted and cells were measured in the same channel. Flow cytometry analysis was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. The recommended titers of respective antibodies from different suppliers were used.
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD132 (REA403). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REA403 recognizes the mouse CD132 antigen, a 65-70 kDa single-pass type I membrane protein also known as common γ chain, which is shared by the IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 receptors. CD132 is expressed on T and B lymphocytes, NK cells, monocytes, and granulocytes. It is involved in intracellular signal transduction by associating with effector molecules within the cytoplasm. The most common form of severe combined immune deficiency in humans, with lack of circulating T cells, a normal or increased number of B lymphocytes, and an X-linked pattern of inheritance (XSCID) has been shown to be due to defects of the CD132 gene.
Additional information: Clone REA403 displays negligible binding to Fc receptors.
IL2RG, IL-2RG, IL2RG, p64, IL-2Rγ
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- DiSanto, J. P. et al. (1994) The murine interleukin-2 receptor gamma chain gene: organization, chromosomal localization and expression in the adult thymus. Eur. J. Immunol. 24 (12): 3014-3018
- Andersson, A. et al. (1997) Mouse macrophage development in the absence of the common gamma chain: defining receptor complexes responsible for IL-4 and IL-13 signaling. Eur. J. Immunol. 27 (7): 1762-1768
- Kumaki, S. et al. (1993) Cloning of the mouse interleukin 2 receptor gamma chain: demonstration of functional differences between the mouse and human receptors. Biochem. Biophys. Res. Commun. 193 (1): 356-363